CA
NZ
UK
AU
IND
US
• Primary Endpoint Missed: Fasedienol showed a -9.5 SUDS change versus -11.4 for placebo, a statistically insignificant difference (p=0.427).
• $21 Million Secured: Decoy Therapeutics closed a private placement at $5.91 per share with a dedicated healthcare investor.
• Primary Endpoint Met With Strong Effect Size: Epcoritamab plus lenalidomide significantly improved PFS over R-GemOx in relapsed/refractory DLBCL.
• $100 Million Raised at $20.00 Per Share: Nuvectis priced a public offering to bolster its balance sheet and fund pipeline expansion.
• Seeking Global Endpoint Harmonization: OS Therapies requested an FDA Type B meeting to align OST-HER2 trial endpoints with international (FDA-EMA) standards.
• Manageable Safety Profile: Treatment-related adverse events were limited to Grade 1–2 severity, with no dose-limiting toxicities reported.
• Mill Margins Under Severe Pressure: Chinese steel mill profitability has fallen to about 51%, reflecting a sharp deterioration in sector economics in recent weeks.
• Speculation-Driven Price Decline: Lithium carbonate fell to a three-month low based on restart speculation alone, without formal confirmation from CATL.
• Titanium Shows Sustained Weakness: Titanium fell to 47.50 CNY/KG on June 30, down 2.06% daily and nearly 6% year-on-year, reflecting persistent price softness.
• Strong Response in Induction Non-Responders: 37.2% of patients who did not respond during induction achieved clinical remission with continued obefazimod treatment.
Please wait processing your request...